Canada - English - Health Canada

sterimax inc - mercaptopurine - tablet - 50mg - mercaptopurine 50mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

alpha pharmaceuticals limited - allopurinol 100mg - tablet - 100 mg - active: allopurinol 100mg excipient: lactose monohydrate magnesium stearate maize starch purified water sodium starch glycolate starch

New Zealand - English - Medsafe (Medicines Safety Authority)

alpha pharmaceuticals limited - allopurinol 300mg - tablet - 300 mg - active: allopurinol 300mg excipient: lactose monohydrate magnesium stearate maize starch purified water sodium starch glycolate starch

Canada - English - Health Canada

pro doc limitee - allopurinol - tablet - 100mg - allopurinol 100mg - antigout agents

Canada - English - Health Canada

pro doc limitee - allopurinol - tablet - 300mg - allopurinol 300mg - antigout agents

Canada - English - Health Canada

pro doc limitee - allopurinol - tablet - 200mg - allopurinol 200mg - antigout agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - allopurinol - oral tablet - 300mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: powdered cellulose; povidone; macrogol 4000; crospovidone; purified talc; magnesium stearate; microcrystalline cellulose - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. management of 2,8-dihydroxyadenine (2,8-dha) renal stones relate to deficient activity of adenine phosphoribosyl transferase. management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: powdered cellulose; povidone; macrogol 4000; crospovidone; purified talc; magnesium stearate; microcrystalline cellulose - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. management of 2,8-dihydroxyadenine (2,8-dha) renal stones relate to deficient activity of adenine phosphoribosyl transferase. management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - allopurinol 100mg;   - tablet - 100 mg - active: allopurinol 100mg   excipient: crospovidone macrogol 4000 magnesium stearate microcrystalline cellulose povidone powdered cellulose purified talc